Warby Parker (WRBY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.15
- Estimate
- $0.11
- Surprise
- +30.0%
- Revenue (period 2026-06-30)
- $235.5M
- Score at report (before → after)
- 4.5 → 4.5/10
Revenue source: xbrl.
How the report landed
Warby Parker (WRBY) beat the $0.11 estimate with adjusted EPS of $0.15 — a large 30.0% upside surprise. TrendMatrix's engine moved from Sell (4.5/10) to Hold at 4.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates WRBY Sell at 4.9/10.
2 of the last 4 quarters beat the estimate; this quarter's +30.0% surprise compares with a +3.4% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.4)
- Weak overall score: 4.9/10
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $23.95
- Price target
- $26.50
- Stop
- $22.28
- Upside to target
- +10.6%
- Reward-to-risk
- 0.9:1
The stock trades at 409.8× trailing but 40.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-16 — shown for context, not personalized investment advice.
WRBY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $3.04B
- P/E (fwd)
- 40.0
- P/E (ttm)
- 409.8
- 52-week range
- $14.96–$31.00
- Off 52-week high
- 22.7%
- RSI (14)
- 47
- Volume vs avg
- 0.29×
- Score today
- 4.9/10